GlassScriptPhysician profile
Dennis Eugene Brodsky
NPI 1235649039
$9,960.94
in general payments reported to CMS, 2019-2025
43 companies · $2,199 in 2025
The $2,199 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,524 · 2022: $1,240 · 2023: $2,712 · 2024: $2,286 · 2025: $2,199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,196.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,818.53 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $1,549.65 | 2021-2025 | Belbuca, Xtampza |
| Nevro Corp. | $1,530.23 | 2021-2024 | Senza |
| Relievant Medsystems, INC. | $450.15 | 2022-2023 | Intracept |
| Saluda Medical Americas, INC. | $438.34 | 2025 | Evoke |
| Boston Scientific Corporation | $430.77 | 2021-2025 | Intracept |
| Pfizer INC. | $303.69 | 2023-2025 | |
| Nalu Medical, INC. | $291.12 | 2021-2024 | Nalu Neurostimulation System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $278.12 | 2023-2025 | Relistor |
| Forte Bio-Pharma LLC | $267.05 | 2023-2024 | Prolate, Nalocet |
| Globus Medical, INC. | $260.93 | 2025 | Senza, Vyrsa V1 |
| Merz Pharmaceuticals, LLC | $219.10 | 2021-2025 | Xeomin |
| Lilly USA, LLC | $198.08 | 2021-2024 | Emgality, Reyvow |
| Si-Bone, INC. | $174.80 | 2024 | |
| Azurity Pharmaceuticals, INC. | $149.96 | 2023-2025 | Horizant, Horizant |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $142.71 | 2021-2024 | Ajovy |
| Impel Pharmaceuticals INC. | $131.26 | 2023 | Trudhesa |
| Medtronic, INC. | $116.61 | 2022-2024 | Intellis Adaptivestim, Synchromedii |
| Tersera Therapeutics LLC | $116.40 | 2025 | Prialt |
| Arbor Pharmaceuticals, INC. | $110.84 | 2021-2022 | |
| Virtus Pharmaceuticals LLC | $101.57 | 2025 | Levorphanol Tartrate |
| Lundbeck LLC | $99.61 | 2022-2025 | Vyepti |
| Spinal Simplicity, LLC | $84.96 | 2023-2025 | Ha Minuteman G3-R |
| Amgen INC. | $76.86 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $68.71 | 2022-2023 | Seglentis |
| Impel Pharmaceuticals LLC | $65.14 | 2025 | Trudhesa |
| Averitas Pharma INC. | $57.95 | 2025 | Qutenza |
| Ipsen Biopharmaceuticals, INC | $57.37 | 2025 | Dysport |
| Abbott Laboratories | $47.64 | 2023-2024 | Prodigy, Proclaim |
| Novo Nordisk INC | $47.58 | 2023 | Wegovy, Saxenda |
| Axsome Therapeutics, INC. | $33.02 | 2025 | Symbravo |
| Mml US, INC. | $32.39 | 2025 | Reactiv8 |
| Hikma Pharmaceuticals USA | $29.96 | 2022 | |
| Glaxosmithkline, LLC. | $24.03 | 2021 | |
| Allergan, INC. | $21.97 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $19.87 | 2025 | |
| Pacira Therapeutics, INC. | $18.90 | 2021 | |
| Alnylam Pharmaceuticals INC. | $17.44 | 2023 | Amvuttra |
| Scilex Pharmaceuticals INC. | $17.38 | 2025 | |
| Almatica Pharma LLC | $16.55 | 2021 | |
| Ibsa Pharma INC. | $16.17 | 2023 | Tirosint, Licart |
| Tonix Medicines, INC. | $15.73 | 2025 | Tonmya |
| Redhill Biopharma INC. | $11.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Brodsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.